Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (18)

« Back to Publications

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic Plasmodium falciparum sporozoite challenge in mice.

Turan G. et al, (2026), Front Immunol, 17

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Mukhopadhyay ES. et al, (2026), Vaccine, 69

Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.

Mukhopadhyay ES. et al, (2025), Vaccine, 68

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice.

Mukhopadhyay E. et al, (2025), Front Immunol, 16

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.

Reinke S. et al, (2023), Cell Rep Med, 4

Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.

Mukhopadhyay E. et al, (2022), Biotechnol Bioeng, 119, 2784 - 2793

Virus-like particle vaccines

Mukhopadhyay E. et al, (2022), 163 - 176

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818

Efficacy of a low dose candidate malaria vaccine, R21 in adjuvant Matrix-M™, with seasonal administration to children in Burkina Faso

EWER K. et al, (2021), The Lancet

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M. et al, (2021), Lancet, 397, 99 - 111

Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites.

Kolli SK. et al, (2021), PLoS One, 16

Load More